Sign In

D. Kyle Hogarth, MD, FCCP

Professor Of Medicine at University of Chicago

D. Kyle Hogarth, MD, FCCP, is a prominent figure in the field of pulmonary medicine, currently serving as a Professor of Medicine in the Section of Pulmonary and Critical Care Medicine at the University of Chicago. He is also the Director of Bronchoscopy and Co-Director of the Lung Cancer Screening Program at the same institution.

Education and Training

Dr. Hogarth earned his medical degree from Case Western Reserve University School of Medicine in 1998. He completed his residency in Internal Medicine and a fellowship in Pulmonary and Critical Care Medicine at the University of Chicago, finishing in 2004. Additionally, he holds a Bachelor of Arts degree with a triple major in Chemistry, Biology, and Microbiology from Miami University, obtained in 1994.124

Clinical and Research Focus

Dr. Hogarth specializes in minimally invasive techniques for diagnosing and treating lung cancer, including advanced bronchoscopy procedures. He was a pioneer in Illinois for using the superDimension electromagnetic navigation system and the Auris Monarch robotic bronchoscope, which enhances the ability to detect and biopsy lung nodules and masses. He has also performed the first bronchial thermoplasty procedures in Illinois, a technique approved by the FDA for treating severe asthma.156

His research interests include improving outcomes for patients with Alpha-1 Antitrypsin Deficiency and lung cancer, and he has authored numerous publications in prestigious medical journals like the New England Journal of Medicine and Chest. Dr. Hogarth serves on the editorial board of CHEST as the section editor for its podcast section and has received various awards for his clinical and teaching excellence.12367

Professional Affiliations

Dr. Hogarth is a founding member and past president of the Society for Advanced Bronchoscopy, and he is actively involved in various medical societies, including the American College of Chest Physicians and the American Thoracic Society.156

Summary

In summary, D. Kyle Hogarth, MD, FCCP, is a distinguished professor and clinician at the University of Chicago, recognized for his contributions to pulmonary medicine, particularly in the areas of advanced bronchoscopy and interventional pulmonary techniques. His work significantly impacts the diagnosis and treatment of lung diseases, enhancing patient care through innovative approaches.

Highlights

Aug 29 · linkedin

So one of the newest areas of growth for our nodule biopsy program using the Galaxy from Noah Medical has been re-do bronchoscopy after a failed attempt with the Ion by Intuitive. Here is a recent and great example of one such case: LLL nodule found after a CXR for cough. CT scan done with "Ion protocol" at another facility with 0.6mm cuts. Bronch done by a good physician with experience using the Ion. Unfortunately for the patient, it was a non-diagnostic bronch AND was complicated by a large pneumothorax requiring a chest tube and overnight stay.
The inability to fix CT to Body Divergence that is inherent in Shape Sensing (and EMN) is one of the fatal flaws of the first generation of robotics. So we grabbed the galaxy and used the same CT from the other facility. TILT allowed us to see the lesion in real-time (using my old crappy c-arm) without needing cone-beam. We could then biopsy through the wall of the airway with certainty (as we didn't have to remove our optics) and avoid the "cloud biopsy" to try and get lucky and make a diagnosis. Our bronchoscopy with the Galaxy was diagnostic for carcinoma and without a pneumothorax and with minimal radiation dose to the patient and the team. And no costs to clean the scope as we threw it away when we were done. Image integrated targeting is what makes the only 2nd generation robot so incredible.

Aug 26 · linkedin

Great case today: patient had prior history of SBRT to a RUL lung nodule and now a new RUL nodule appeared on follow up. This was 5.4mm x 8.1mm and on the pleura. Navigated to the lesion (2 minutes), first biopsy was positive for adeno, fiducial left behind, no PTX. Oh, and only 7mGy exposure to the patient and the team and no one EVER left the room. And I wasn't forced to go purchase over-priced fluoroscopy systems to compensate for the inability to fix CTBD that happens with shape sensing (and EMN). Then we threw the scope away and didn't have to waste time and money re-processing a scope that starts to have lag on further uses. Image-integrated Targeting with the 2nd generation robot is the key to successful peripheral bronchoscopy. Noah Medical

Related Questions

What are Dr. Hogarth's most notable contributions to the field of advanced bronchoscopy?
How has Dr. Hogarth's work impacted the treatment of severe asthma?
What are the latest advancements in robotic bronchoscopy according to Dr. Hogarth?
Can you provide more details on the clinical trials Dr. Hogarth is involved in?
What makes Dr. Hogarth's approach to lung cancer diagnosis unique?
D. Kyle Hogarth, MD, FCCP
D. Kyle Hogarth, MD, FCCP, photo 1
D. Kyle Hogarth, MD, FCCP, photo 2
Add to my network

Location

Greater Chicago Area